A platform for identifying new antibiotics designed to combat multidrug-resistant bacteria

An app is developed based on intangible cultural heritage to prevent memory loss in elderly people
July 21, 2021
Drones to control capacity
July 8, 2021
9/07/2021

inLab FIB is collaborating with the company ABAC Therapeutics (ABAC) to develop a drug discovery platform to identify new antibiotics designed to combat multidrug-resistant bacteria.



ABAC Therapeutics is a company that investigates new antibiotics for certain pathogens and develops treatment solutions against multiantibiotic-resistant bacteria. ABAC uses its own drug discovery platform PasNas to identify new antibiotics designed to combat multidrug-resistant bacteria for patients infected with bacterial pathogens that are highly resistant to antibiotics that leave patients affected with few (or no) treatment options. This new strategy enables the identification of compounds with specific activity and new mechanisms of action that do not harm human bacterial flora and minimise the selection of resistant strains.

inLab FIB is in charge of developing the computer platform that supports the analysis of data from experimental processes.

The project has been developed in two periods: an initial period from July 2018 to January 2019 and an extension of the project from July 2020 until December 2021.